Valeocor-Q10® (Valeocor-Q10)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceUbidecarenoneUbidecarenone
Similar drugsTo uncover
  • Valeocor-Q10®
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Kudevita®
    capsules inwards 
    PIK-PHARMA, LLC     Russia
  • Coudesan®
    drops inwards 
    VNESHTORG PHARMA, LLC     Russia
  • Kudesan® for children
    pills inwards 
    RUSFIK, LLC     Russia
    • Dosage form: & nbsp

    chewing tablets

    Composition:

    For 1 tablet:

    Active substance: ubedecarenone 50.0 mg.

    Excipients: macrogol-6000 500.1 mg, isomalt 80.7 mg, carmellose sodium 35.0 mg, ascorbic acid 30.0 mg, sodium stearyl fumarate 3.5 mg, aspartame 0.7 mg.

    Weight of the tablet is 700 mg.

    Description:Round smooth tablets with a facet and a risk, orange with a small amount of white impregnations.
    Pharmacotherapeutic group:Cardiotonic agent of non-glycosidic structure
    ATX: & nbsp

    C.01.E.X   Other combination drugs for the treatment of heart disease

    C.01.E.X.09   Ubidecarenone

    Pharmacodynamics:

    Ubidekarenone (coenzyme Q10, ubiquinone) is a natural substance that is a vitamin-like coenzyme. Ubidecarenone is an endogenous substrate, takes part in the transfer of electrons in the transport chain of oxidation-reduction processes, in the process of metabolism, energy, in, the reaction of oxidative phosphorylation in the respiratory chain of mitochondria of cells. Participates in the processes of cellular respiration, increasing the synthesis of adenosine triphosphate (ATP). Has a clinically significant antioxidant effect. Ubidecarenone protects lipids of cell membranes from peroxidation. Reduces the area of ​​damage to the myocardium under conditions of ischemia and reperfusion.

    Ubidecarenone prevents the prolongation of the Q-T interval, improves the tolerance of exercise. Due to endogenous synthesis 100% satisfaction of the body's need for coenzyme Q10 occurs only up to the age of 20 years. Concentration of coenzyme Q10 decreases in elderly patients, as well as in various diseases, both in adults and in children.

    Pharmacokinetics:Clinical studies of the pharmacokinetics of the drug have not been conducted. Experimental studies in animals have shown that after ingestion the drug is rapidly absorbed, the maximum concentration in the plasma is reached 1 hour after admission (Tmax). The drug is excreted in the urine in an unchanged form and in the form of metabolites. Half-life (T1/2) is 2 hours. Biological availability of the drug is 20%.
    Indications:

    In the complex therapy of coronary heart disease (including myocardial infarction - the period of restorative therapy), chronic heart failure, arterial hypertension.

    For prevention and replacement of coenzyme Q10 deficiency.

    To improve the adaptation to increased physical exertion in athletes.

    Contraindications:Severe arterial hypotension (blood pressure below 90/60 mm Hg). Hypersensitivity to the components of the drug. Acute glomerulonephritis, stomach and duodenal ulcer (at the stage of exacerbation), severe bradycardia (heart rate less than 50 beats per minute), pregnancy, breast-feeding period.
    Carefully:With arterial hypotension, take with caution.
    Pregnancy and lactation:The drug is not recommended for use during pregnancy and lactation, as strictly controlled clinical studies of safety of the drug in pregnant and lactating women were not carried out.
    Dosing and Administration:

    As a part of complex therapy in the treatment of coronary heart disease and chronic heart failure, 3 tablets (150 mg) per day, divided into 3 doses, are used. Tablets chew.

    In complex therapy of arterial hypertension, to compensate for the deficiency of coenzyme Q10 and improve adaptation to increased physical activity, athletes use 1 to 2 tablets (50 to 100 mg) per day. Tablets chew.

    The duration of the course of the drug is 1 - 3 months.

    Side effects:

    Possible diarrheal phenomenon (heartburn, epigastric pain, nausea, vomiting, diarrhea). Reduction of blood pressure, tachycardia.

    Allergic reactions are possible (reddening of the skin, itching of the skin, swelling of the nasal mucosa, allergic conjunctivitis).

    Overdose:Cases of drug overdose are not known.
    Interaction:Potentiates the pharmacological effects of cardiotonic, antihypertensive, antianginal drugs. Simultaneous use of lipid-lowering agents (inhibitors of HMG-CoA reductase, fibrates), beta-blockers (atenolol, metoprolol, propranolol), warfarin, tricyclic antidepressants can lead to a decrease in the concentration of ubidecarenone in the blood plasma.
    Effect on the ability to drive transp. cf. and fur:There is no evidence of adverse effects of the drug on the ability to drive vehicles and mechanisms.
    Form release / dosage:Tablets chewing on 50 mg.
    Packaging:For 10 tablets in a planar cell packaging made of polyvinylchloride film and foil; one, two, three, four or five contour packagings together with instructions for use in a pack of cardboard.
    Storage conditions:Store in a dry, dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.
    Shelf life:2 years. Do not use after the time specified on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LP-000650
    Date of registration:28.09.2011
    Expiration Date:28.09.2016
    The owner of the registration certificate:FARMASOFT NPK, LLC FARMASOFT NPK, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp14.01.2017
    Illustrated instructions
      Instructions
      Up